Fast Locator 2011-2012: Cangene bioPharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Cangene bioPharma



CANGENE bioPharma, is a contract manufacturer, providing fill/finish and support services for over 30 years. Located in Baltimore, MD, USA, close to the FDA, CANGENE bioPharma is highly compliant, having successfully passed inspections from numerous regulatory agencies in the US, EU, and Japan.

CANGENE bioPharma’s fill/finish services include:

  • Vial filling (3cc-100cc) - batches up to 85,000 5cc vials
  • Lyophilization (2 x 240 sq ft lyophilizers)
  • Syringe filling – 0.5cc–20cc syringes
  • Terminal Sterilization – with steam

CANGENE bioPharma prides itself on providing outstanding and flexible support to its partner companies. From clinical through commercial launch, CANGENE bioPharma has the experience, knowledgeable personnel and involved management team to ensure our partners’ products proceed from project initiation through manufacturing quickly with an emphasis on exceptional quality.

CANGENE bioPharma provides services to a worldwide customer base, including large, small and virtual pharmaceutical and biotechnology companies. CANGENE bioPharma produces products that are distributed in over 50 countries by our clients.


Regions covered:

North America


Outsourcing services provided:

Development and Phase I/II CTM

  • Injectable products development

Commercial Manufacturing

  • Injectables

Analytical Services

  • Chemistry and stability
  • Microbiology

Website:

www.cangenebiopharma.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here